List of Excipients in Branded Drug SPIRONOLACTONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis US LLC	SPIRONOLACTONE	spironolactone	0574-1133	AMMONIUM GLYCYRRHIZATE
Padagis US LLC	SPIRONOLACTONE	spironolactone	0574-1133	ANHYDROUS CITRIC ACID
Padagis US LLC	SPIRONOLACTONE	spironolactone	0574-1133	DIMETHICONE
Padagis US LLC	SPIRONOLACTONE	spironolactone	0574-1133	GLYCERIN
Padagis US LLC	SPIRONOLACTONE	spironolactone	0574-1133	POTASSIUM SORBATE

Generic Drugs Containing SPIRONOLACTONE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc.	spironolactone	0378-2146	CALCIUM SULFATE DIHYDRATE
Mylan Pharmaceuticals Inc.	spironolactone	0378-2146	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc.	spironolactone	0378-2146	CROSPOVIDONE
Mylan Pharmaceuticals Inc.	spironolactone	0378-2146	HYPROMELLOSE 2910
Mylan Pharmaceuticals Inc.	spironolactone	0378-2146	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in SPIRONOLACTONE?

# Of NDCs	Excipient
3	AMMONIUM GLYCYRRHIZATE
1	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
47	ANHYDROUS LACTOSE
24	CALCIUM SULFATE
75	CALCIUM SULFATE DIHYDRATE

Excipient Strategy and Commercial Opportunities for Spironolactone

Last updated: February 26, 2026

What are the key excipient considerations for spironolactone formulations?

Spironolactone is a potassium-sparing diuretic primarily used for heart failure, hypertension, and certain endocrine disorders. Its formulation challenges include low aqueous solubility and potential stability issues, impacting bioavailability and shelf life.

Common excipients used with spironolactone:

• Binders: Microcrystalline cellulose (Filler and binder)
• Disintegrants: Crospovidone, croscarmellose sodium
• Filling agents: Lactose, Dextrin
• Lubricants: Magnesium stearate
• Coating agents: Hydroxypropyl methylcellulose (HPMC), Polyvinyl alcohol (PVA)
• Solubilizers: Surfactants like sodium lauryl sulfate (SLS) in some formulations

Formulation strategies include:

• Microencapsulation to improve stability
• Use of polymers for controlled release
• Incorporation of solubilizing agents to improve bioavailability of poorly soluble spironolactone

How do excipient choices influence bioavailability and stability?

Bioavailability considerations:

• Spironolactone's poor water solubility (BCS Class II) necessitates solubilizing excipients or lipid-based formulations.
• Surfactants enhance dissolution, increasing absorption.
• Controlled-release excipients enable sustained plasma concentrations, reducing dosing frequency.

Stability considerations:

• Excipients that minimize hydrolysis and oxidation (e.g., antioxidants like ascorbyl palmitate) extend shelf life.
• Protective film coatings shield active compound from moisture and oxygen.
• Proper pH buffering agents can prevent acid- or base-catalyzed degradation.

What are the commercial opportunities related to excipient innovations?

Market size and growth:

• The global spironolactone market was valued at USD 0.6 billion in 2021 and is projected to grow at a CAGR of approximately 5% through 2028 (Grand View Research, 2022).
• Larger market segments include generic formulations, which account for over 80% of sales.

Opportunities:

• Development of novel controlled-release formulations improves patient compliance and can command premium pricing.
• Incorporating bioenhancers and solubilizing excipients enhances drug absorption, potentially expanding indications.
• Formulations with improved stability profiles can extend shelf life and reduce distribution costs.
• Patient-centric delivery systems, such as orally disintegrating tablets, open access to pediatric and geriatric populations.

Regulatory and patent landscape:

• Existing patents primarily cover the active molecule; excipient innovations may provide opportunities for new proprietary formulations.
• Patent-expiry of original formulations (e.g., 2015 in the US) presents opportunities for new formulations with differentiated excipients.

Manufacturing considerations:

• Cost-effective excipients with proven safety profiles accelerate regulatory approval.
• Compatibility with existing manufacturing processes reduces entry barriers.

How do regulatory frameworks influence excipient strategies?

• Agencies such as the FDA and EMA specify requirements for excipient safety, compatibility, and quality.
• Demonstrating excipient safety and stability is essential for approval of modified formulations.
• New excipients or novel use of existing excipients may require additional toxicology data and clinical validation.

Summary table: Excipient features and formulation approaches

Aspect	Key Excipients / Strategies	Purpose
Solubility enhancement	Surfactants (SLS), lipid-based excipients	Improve bioavailability
Stability improvement	Antioxidants, pH buffers, protective coatings	Extend shelf life, prevent degradation
Controlled release	Hydrophilic polymers (HPMC), matrix-forming agents	Sustained drug levels
Patient acceptability	Orally disintegrating tablets, flavoring agents	Improve compliance

Key Takeaways

• Excipient selection for spironolactone hinges on solubility, stability, and release profile.
• Formulation innovation focused on controlled-release and bioavailability can drive premium market offerings.
• Patent landscape shifts open opportunities for proprietary formulations with novel excipients.
• Regulatory compliance demands rigorous safety validation of excipients, especially for new delivery methods.
• Cost-efficient, scalable excipient strategies support manufacturing and distribution.

FAQs

1. Which excipients are most critical for improving spironolactone bioavailability?
Surfactants like sodium lauryl sulfate and lipid-based carriers significantly increase solubility and absorption.

2. Are there existing patents related to excipient innovations for spironolactone?
Yes. Many patents cover modified forms and controlled-release formulations, creating opportunities for further excipient-innovative filings, especially beyond 2015 patent expiries.

3. How does formulation impact patient compliance?
Extended-release and orally disintegrating tablet formats improve adherence by reducing dosing frequency and enhancing ease of administration.

4. What regulatory hurdles exist for excipient substitutions?
New excipients require safety and compatibility data, while changes to existing excipients or formulations may trigger supplemental filings and bioequivalence studies.

5. What markets show the highest potential for innovative spironolactone formulations?
Developing countries with high prevalence of hypertension and heart failure, and premium markets focusing on improved safety and compliance, present growth opportunities.

---

References

1. Grand View Research. (2022). Spironolactone Market Size, Share & Trends Analysis Report.
2. U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Pharmaceutical Bajor.
3. World Health Organization. (2019). WHO Model List of Essential Medicines.